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Background-—The impact of hemoglobin levels and anemia on stroke mortality remains controversial. We aimed to systematically
assess this association and quantify the evidence.
Methods and Results-—We analyzed data from a cohort of 8013 stroke patients (meanSD, 77.8111.83 years) consecutively
admitted over 11 years (January 2003 to May 2015) using a UK Regional Stroke Register. The impact of hemoglobin levels and
anemia on mortality was assessed by sex-speciﬁc values at different time points (7 and 14 days; 1, 3, and 6 months; 1 year) using
multiple regression models controlling for confounders. Anemia was present in 24.5% of the cohort on admission and was
associated with increased odds of mortality at most of the time points examined up to 1 year following stroke. The association was
less consistent for men with hemorrhagic stroke. Elevated hemoglobin was also associated with increased mortality, mainly within
the ﬁrst month. We then conducted a systematic review using the Embase and Medline databases. Twenty studies met the
inclusion criteria. When combined with the cohort from the current study, the pooled population had 29 943 patients with stroke.
The evidence base was quantiﬁed in a meta-analysis. Anemia on admission was found to be associated with an increased risk of
mortality in both ischemic stroke (8 studies; odds ratio 1.97 [95% CI 1.57–2.47]) and hemorrhagic stroke (4 studies; odds ratio
1.46 [95% CI 1.23–1.74]).
Conclusions-—Strong evidence suggests that patients with anemia have increased mortality with stroke. Targeted interventions in
this patient population may improve outcomes and require further evaluation. ( J Am Heart Assoc. 2016;5:e003019 doi:
10.1161/JAHA.115.003019)
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A nemia is common in patients presenting with acutestroke. Hospital-based studies have reported prevalence
up to 30%.1,2 Although anemia has been independently
associated with increased mortality in a variety of conditions
including chronic kidney disease,3 heart failure,4 and acute
coronary syndromes,5 observational studies investigating the
association between anemia and mortality in stroke have
shown conﬂicting results. Early studies found no association
between anemia and stroke outcomes6,7; however, others
have found both low and high hemoglobin levels to be
associated with increased mortality,8–10 suggesting a U-
shaped relationship. Guidelines have been unable to specify
the optimal treatment options for acute stroke patients with
anemia.11
Previous studies were limited by small sample sizes, and a
majority did not report outcomes by stroke subtype. In
addition, no previous study stratiﬁed analysis by sex-speciﬁc
hemoglobin levels. This is particularly important because of
the natural variance in the normal hemoglobin ranges
between sexes. The literature describes various plausible
mechanisms that explain how anemia could directly con-
tribute to poor outcomes.12 There is a paucity of information,
however, investigating the impact of an important clinical
factor: whether stroke patients with anemia receive fewer
preventative medications pertinent to stroke, such as
antiplatelets and anticoagulants (antithrombotics). In addition,
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Table 1. Sex-Speciﬁc Sample Characteristics by Anemia Status
Male Female
Anemia No Anemia P Value Anemia No Anemia P Value
Number 1017 (26.7) 2794 (73.3) 947 (22.5) 3255 (77.5)
Age, y <0.001 <0.001
≤60 46 (4.5) 424 (15.2) 29 (3.1) 208 (6.4)
61–65 32 (3.1) 282 (10.1) 21 (2.2) 143 (4.4)
66–70 50 (4.9) 340 (12.2) 33 (3.5) 231 (7.1)
71–75 127 (12.5) 411 (14.7) 65 (6.9) 344 (10.6)
76–80 187 (18.4) 470 (16.8) 137 (14.5) 522 (16.0)
81–85 247 (24.3) 475 (17.0) 232 (24.5) 747 (22.9)
86–90 234 (23.0) 279 (10.0) 253 (26.7) 635 (19.2)
≥91 94 (9.2) 113 (4.0) 177 (18.7) 435 (13.4)
Prestroke comorbidity
Coronary heart disease 304 (29.9) 446 (16.0) <0.001 230 (24.3) 475 (14.6) <0.001
Previous stroke 287 (28.2) 607 (21.7) <0.001 261 (27.6) 763 (23.4) 0.009
Congestive heart failure 143 (14.1) 154 (5.5) <0.001 147 (15.5) 255 (7.8) <0.001
Atrial fibrillation 217 (21.3) 307 (11.0) <0.001 206 (21.8) 508 (15.6) <0.001
Hypertension 422 (41.5) 650 (23.3) <0.001 393 (41.5) 1044 (32.1) <0.001
Hyperlipidemia 76 (7.5) 99 (3.5) <0.001 42 (4.4) 135 (4.1) 0.698
Diabetes mellitus 183 (18.0) 231 (8.3) <0.001 137 (14.5) 242 (7.4) <0.001
Peripheral vascular disease 63 (6.2) 49 (1.8) <0.001 28 (3.0) 61 (1.9) 0.042
GI bleeding and peptic ulcer 81 (8.0) 118 (4.2) <0.001 62 (6.5) 142 (4.4) 0.006
COPD 90 (8.8) 113 (4.0) <0.001 65 (6.9) 107 (3.3) <0.001
Chronic kidney disease 93 (9.1) 37 (1.3) <0.001 50 (5.3) 69 (2.1) <0.001
Falls 161 (15.8) 160 (5.7) <0.001 275 (29.0) 557 (17.1) <0.001
Malignancy 240 (23.6) 274 (9.8) <0.001 112 (11.8) 278 (8.5) 0.002
Dementia 47 (4.6) 43 (1.5) <0.001 75 (7.9) 121 (3.7) <0.001
Prior antithrombotic use <0.001 0.286
No 447 (44.0) 1538 (55.0) 499 (52.7) 1779 (54.7)
Yes 570 (56.0) 1256 (45.0) 448 (47.3) 1476 (45.3)
Prestroke Rankin Scale score* <0.001 <0.001
0 556 (54.7) 2119 (75.8) 388 (41.0) 1955 (60.1)
1 155 (15.2) 286 (10.2) 135 (14.3) 399 (12.3)
2 96 (9.4) 147 (5.3) 121 (12.8) 303 (9.3)
3 131 (12.9) 142 (5.1) 160 (16.9) 354 (10.9)
4 54 (5.3) 73 (2.6) 90 (9.5) 176 (5.4)
5 25 (2.5) 27 (1.0) 53 (5.6) 68 (2.1)
Stroke type 0.088 0.002
Hemorrhagic 121 (11.9) 392 (14.0) 95 (10.0) 454 (13.9)
Ischemic 896 (88.1) 2402 (86.0) 852 (90.0) 2801 (86.1)
OCSP classification 0.002 <0.001
TACS 215 (21.1) 500 (17.9) 248 (26.2) 699 (21.5)
PACS 359 (35.3) 900 (32.2) 312 (32.9) 1084 (33.3)
Continued
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there is a lack of data regarding the comorbidity burden in
anemic stroke patients and inadequate control for this in
statistical analyses.
The current study aimed to clarify these important
questions by assessing the impact of admission hemoglobin
levels and anemia on stroke mortality at different time points
up to 1-year follow-up. A systematic review and meta-analysis
were also carried out to further quantify the impact of
admission hemoglobin and anemia on stroke mortality
outcomes.
Methods
Database Study
The study population consisted of 8013 patients with acute
stroke who were admitted consecutively between January
2003 and May 2015 to Norfolk and Norwich University
Hospital, a regional tertiary center in East Anglia, UK, with a
catchment population of 750 000. Ethics approval was
obtained from the Newcastle and Tyneside National Health
Service Research Ethics Committee (12/NE/0170), and the
study protocol was approved by the steering committee of the
register used. Individual patients were not required to provide
written informed consent because this source is a research
database register that included all consecutive patients.
The data collection methods for this prospective hospital-
based register have been reported previously.13 Brieﬂy, the
data were obtained from paper and electronic records,
reviewed, and then entered into the register database. This
was done by the hospital stroke data team and vetted by
clinical team members for accuracy. For each patient
admitted, the prestroke modiﬁed Rankin Scale score (scores
are deﬁned in Table 1), as modiﬁed by UK-TIA investigators,14
was ascertained from nursing and medical records by stroke
specialist nurses. At discharge, deceased or living status was
recorded to capture in-hospital mortality. Follow-up for
mortality was obtained by electronic record linkage with the
Ofﬁce of National Statistics data through hospital episodes in
May 2015. For the purposes of this study, the follow-up was
truncated at 365 days for all patients.
The variables included were age, sex, stroke subtype
(ischemic or hemorrhagic), prestroke disability depicted by
modiﬁed Rankin Scale score (0–5), Oxfordshire Community
Stroke Project (OCSP) classiﬁcation (total anterior circulation
stroke, partial anterior circulation stroke, posterior circulation
stroke, lacunar stroke), hemoglobin levels at admission,
comorbidities (coronary heart disease, congestive heart
failure, atrial ﬁbrillation, hypertension, hyperlipidemia, previ-
ous stroke, diabetes mellitus, peripheral vascular disease,
gastrointestinal bleeding, peptic ulcers, chronic obstructive
pulmonary disease, chronic kidney disease, falls, malignancy,
dementia), and prior use of antithrombotics. Mortality was
assessed at several different time points: inpatient; at 7 and
14 days; at 1, 3, and 6 months; and at 1 year. Results
were displayed selectively in Tables 2 and 3, and data for the
7- and 14-day time points were not included because of the
similarity in results and to ensure brevity. Only conﬁrmed
cases of stroke were included. Stroke was diagnosed using
evidence from clinical features and neuroimaging (typically
computed tomography and, in some cases, magnetic reso-
nance imaging). Anemia was deﬁned according to the World
Health Organization criteria of hemoglobin <12.0 g/dL in
women and <13.0 g/dL in men, and elevated hemoglobin
was deﬁned as >15.5 g/dL in women and >17.0 g/dL in
men.15
The associations between hemoglobin levels and age, sex,
prestroke modiﬁed Rankin Scale score, stroke type, OCSP
classiﬁcation, comorbidities, prior antithrombotic use, and
inpatient mortality were assessed using the chi-square test.
Logistic regression models were constructed to assess
the impact of hemoglobin levels (by quintiles) and anemia on
Table 1. Continued
Male Female
Anemia No Anemia P Value Anemia No Anemia P Value
POCS 169 (16.6) 548 (19.6) 118 (12.5) 521 (16.0)
LACS 209 (20.6) 696 (24.9) 186 (19.6) 786 (24.1)
Undefined 65 (6.4) 150 (5.4) 83 (8.8) 165 (5.1)
Inpatient mortality <0.001 <0.001
Living 731 (71.9) 2393 (85.6) 635 (67.1) 2546 (78.2)
Deceased 286 (28.1) 401 (14.4) 709 (21.8) 312 (22.5)
The data are presented as number (%) for categorical variables. COPD indicates chronic obstructive pulmonary disease; GI, gastrointestinal; LACS, lacunar stroke; OCSP, Oxfordshire
Community Stroke Project; PACS, partial anterior circulation stroke; POCS, posterior circulation stroke; TACS, total anterior circulation stroke.
*0: no symptoms; 1: no signiﬁcant disability despite symptoms, able to carry out all usual duties and activities; 2: slight disability, unable to perform all previous activities but able to look
after own affairs without assistance; 3: moderate disability, requires some help but able to walk without assistance; 4: moderately severe disability, unable to walk without assistance and
to attend to own bodily needs without assistance; 5: severe disability—bedridden, incontinent, and requiring constant nursing care and attention.
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odds of death. Univariate and multivariate models were
used to calculate unadjusted and adjusted odds ratios (ORs).
Sex- and stroke type–speciﬁc analyses were performed
controlling for age, OCSP classiﬁcation, prestroke modiﬁed
Rankin Scale score, comorbidities, and prior antithrombotic
usage.
To better understand the potential mediating factors for
the observed associations, we examined the distribution of
selected chronic comorbidities between patients with ane-
mia and no anemia and assessed the differences in
proportions of patients receiving antithrombotic medications
by a vascular indication (deﬁned as presence of previous
stroke, coronary heart disease, diabetes mellitus, peripheral
vascular disease, hypertension, and atrial ﬁbrillation). The
analysis was performed using the SPSS version 23.0 (IBM
Corp).
Table 2. The Impact of Hemoglobin Levels on Mortality at Different Time Points (Logistic Regression)
Variable
Hemoglobin quintile
Events1 2 3 4 5
Male ischemic
Number 635 675 667 644 677
Inpatient 2.64 (1.83–3.81) 1.56 (1.08–2.25) 1.00 1.59 (1.06–2.38) 1.62 (1.08–2.42) 511
1 month 2.99 (2.06–4.34) 1.74 (1.19–2.53) 1.00 1.55 (1.03–2.34) 1.79 (1.19–2.68) 488
3 months 3.09 (2.24–4.25) 1.34 (0.96–1.85) 1.00 1.18 (0.82–1.69) 1.37 (0.96–1.95) 674
6 months 2.92 (2.16–3.94) 1.37 (1.01–1.85) 1.00 1.05 (0.75–1.46) 1.16 (0.83–1.63) 796
1 year 2.90 (2.18–3.86) 1.43 (1.08–1.90) 1.00 1.17 (0.86–1.59) 1.17 (0.86–1.60) 971
Male hemorrhagic
Number 83 109 103 87 131
Inpatient 1.23 (0.58–2.60) 0.83 (0.42–1.65) 1.00 0.86 (0.39–1.86) 1.05 (0.53–2.09) 176
1 month 1.22 (0.59–2.51) 0.92 (0.48–1.78) 1.00 0.81 (0.39–1.70) 0.93 (0.48–1.80) 173
3 months 1.16 (0.55–2.42) 0.67 (0.34–1.30) 1.00 0.76 (0.38–1.57) 0.68 (0.35–1.57) 200
6 months 1.65 (0.77–3.55) 0.81 (0.41–1.60) 1.00 0.78 (0.38–1.62) 0.73 (0.38–1.41) 221
1 year 1.97 (0.92–4.22) 0.81 (0.42–1.58) 1.00 0.73 (0.35–1.51) 0.79 (0.41–1.51) 229
Female ischemic
Number 698 748 700 752 755
Inpatient 1.47 (1.08–1.98) 1.05 (0.77–1.43) 1.00 1.39 (1.01–1.90) 1.20 (0.88–1.63) 792
1 month 1.48 (1.09–2.01) 1.16 (0.85–1.58) 1.00 1.23 (0.89–1.69) 1.26 (0.92–1.73) 733
3 months 1.70 (1.28–2.25) 1.16 (0.87–1.54) 1.00 1.34 (1.00–1.79) 1.19 (0.89–1.58) 1007
6 months 1.86 (1.42–2.44) 1.22 (0.93–1.60) 1.00 1.44 (1.09–1.89) 1.26 (0.96–1.67) 1159
1 year 1.86 (1.44–2.41) 1.23 (0.96–1.59) 1.00 1.29 (0.99–1.68) 1.13 (0.87–1.46) 1328
Female hemorrhagic
Number 72 100 132 127 118
Inpatient 2.56 (1.23–5.32) 0.80 (0.41–1.57) 1.00 0.80 (0.54–1.81) 1.35 (0.74–2.47) 229
1 month 2.61 (1.31–5.36) 0.80 (0.42–1.55) 1.00 1.12 (0.62–2.01) 1.46 (0.81–2.63) 226
3 months 2.26 (1.10–4.64) 0.88 (0.47–1.67) 1.00 0.94 (0.53–1.68) 1.22 (0.68–2.19) 256
6 months 2.02 (0.98–4.16) 0.97 (0.52–1.82) 1.00 0.80 (0.45–1.42) 1.22 (0.68–2.18) 278
1 year 2.59 (1.23–5.44) 1.20 (0.64–2.25) 1.00 0.95 (0.54–1.68) 1.35 (0.75–2.41) 292
The cutoff points for the quintiles are as follows: male: 12.4, 13.8, 14.6, and 15.6 g/dL; female: 11.7, 12.8, 13.6, and 14.5 g/dL. The variables adjusted for were age, Oxford Community
Stroke Project classiﬁcation, prestroke Rankin Scale score, prior antithrombotic use, coronary heart disease, previous stroke, congestive heart failure, atrial ﬁbrillation, hypertension,
hyperlipidemia, diabetes mellitus, peripheral vascular disease, chronic obstructive pulmonary disease, chronic kidney disease, falls, malignancy, dementia, gastrointestinal bleeding, and
peptic ulcer. We also adjusted for International Normalized Ratio in patients with hemorrhagic stroke. The International Normalized Ratio was included as a dichotomous categorical
variable: <1.40 versus ≥1.40. Data for the time points 7 and 14 days were removed for brevity. Mean ages for the male quintiles were 82.80, 80.48, 78.49, 78.09, and 78.38 years for
quintiles 1–5, respectively. Mean ages for female quintiles were 83.04, 81.81, 80.45, 78.96, and 78.06 years for quintiles 1–5, respectively.
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Systematic Review and Meta-Analysis
We selected full journal articles reporting on studies that
evaluated the association between baseline hemoglobin or
anemia and subsequent mortality in patients diagnosed with
stroke. PubMed and Embase were searched from inception
until December 2014 using the following search terms with no
language restriction: stroke OR intracranial-hemorrhage OR
intracerebral-hemorrhage AND haemoglobin OR hemoglobin OR
anaemia OR anemia AND mortality OR fatal* OR survival OR
death NOT rivaroxaban OR dabigatran OR apixaban OR sickle
OR surgery OR glycated OR glycosylated OR HbA1C or
erythropoie*. In addition, we checked the bibliographies of
relevant articles for any studies that met our selection criteria.
Two reviewers (R.B. and K.H.) independently screened
abstracts and titles. Potentially relevant studies were reviewed
to conﬁrm their eligibility. The selection and data extraction of
included studies were performed by R.B. and K.H. and checked
Figure 1. Patient inclusion chart. mRS indicates modiﬁed Rankin Scale score; OCSP, Oxfordshire
Community Stroke Project.
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Figure 2. Prevalence of comorbidities by anemia status in men. The vertical line represents the expected
proportion of comorbidity based on the proportion of stroke patients with anemia. Any dark bars to the right
of the vertical line represent higher comorbidity burden in anemic patients comparedwith patientswhowere
not anemic. AF indicates atrial ﬁbrillation; CHD, coronary heart disease; CHF, congestive heart failure; CKD,
chronic kidney disease; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease.
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by a senior reviewer (Y.K.L.). To assess study validity, included
studies were assessed for the methods used for diagnosing
stroke, determination of hemoglobin levels and anemia, ascer-
tainment of mortality or outcome subsequent to the stroke, and
the analytic procedures aimed atminimizing the risk of bias from
confounders. We pooled the reported associations (adjusted OR
if available) using the inverse variance method and random-
effectsmodel inRevMan5.3 software (NordicCochraneCenter).
The comparisons of interest were for categories of anemia
versus no anemia in patients with ischemic and hemorrhagic
stroke versus the referent “normal” category. We evaluated
heterogeneity by calculating the I2 statistic, for which a value
>50%was indicative of substantial heterogeneity.We also aimed
to check for publication bias through a funnel plot if there were
>10 eligible studies in our systematic review.
Results
Database Study
Of the 11 886 episodes recorded in the registry, 3873 were
excluded for various reasons (Figure 1). Overall, 2659 of
these episodes were excluded because of missing data, and
991 were excluded because they were related to secondary
entry into the register due to subsequent stroke. The sample
included in the current study consisted of 8013 patients with
acute stroke admitted consecutively between January 2003
and May 2015. The mean age in the cohort was 77.8111.83
years, 52.4% were women, and 86.7% had ischemic stroke.
The most common OCSP stroke classiﬁcation was partial
anterior circulation stroke (33.1%), and the majority of
patients (62.6%) had a prestroke modiﬁed Rankin Scale score
of 0. Inpatient mortality was 21.3%, and 1 in 4 patients
(24.5%) had anemia on admission.
Table 1 shows sex-speciﬁc sample characteristics by
anemia status. Increasing age, higher prestroke disability,
increased stroke severity, inpatient mortality, and all comor-
bidities (with the exception of hyperlipidemia in women) were
associated with anemia (Figures 2 and 3). Prior antithrom-
botic use in men and ischemic stroke in women were also
associated with anemia.
Table 2 depicts the impact of hemoglobin levels on stroke
mortality by quintiles of sex-speciﬁc admission hemoglobin
levels, presented separately for ischemic and hemorrhagic
stroke. Quintile 1 contains those with the lowest values, and
quintile 5 has the highest. The cutoff points were 12.40, 13.80,
14.64, and 15.60 g/dL for men and 11.70, 12.80, 13.60, and
14.50 g/dL for women. In men with ischemic stroke, low
hemoglobin (quintile 1) was signiﬁcantly associated with
increased mortality at all time points measured compared
with those with normal hemoglobin levels (quintile 3). High
hemoglobin (quintile 5) was also associated with increased
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Figure 3. Prevalence of comorbidities by anemia status in women. The vertical line represents the expected
proportion of comorbidity based on the proportion of stroke patients with anemia. Any dark bars to the right of
the vertical line represent higher comorbidity burden in anemic patients compared with patients who were not
anemic. AF indicates atrial ﬁbrillation; CHD, coronary heart disease; CHF, congestive heart failure; CKD,
chronic kidney disease; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease.
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odds of mortality at 4 time points; inpatient, 7 and 14 days,
and 1 month. This suggested a U-shaped relationship between
hemoglobin levels and short-term mortality in men with
ischemic stroke. In women with ischemic stroke, low
hemoglobin levels were signiﬁcantly associated with mortality
at 5 time points; inpatient; 1, 3, and 6 months; and 1 year. In
women with hemorrhagic stroke, low hemoglobin levels were
associated with increased mortality at all time points.
Table 3 shows the impact of anemia and elevated
hemoglobin levels on mortality. In men with ischemic
stroke, anemia was associated with higher odds of death at
all time points assessed, and elevated hemoglobin was
associated with increased odds of death at 3 time points;
inpatient, 1 month, and 3 months. In men with hemorrhagic
stroke, anemia was associated with increased mortality at
1 year, and elevated hemoglobin was associated with
increased mortality at 4 time points; inpatient, 7 and
14 days, and 1 month. In women with ischemic stroke,
anemia was associated with increased mortality at 1, 3,
and 6 months and 1 year, whereas elevated hemoglobin
was associated with increased mortality at 7 and 14 days
and 1 month. In women with hemorrhagic stroke, anemia
Table 3. Effect of Anemia and Elevated Hemoglobin on Stroke Outcomes at Different Time Points (Logistic Regression)
Anemia Normal Elevated Hemoglobin Events
Male ischemic
Number 896 2277 125
Inpatient 1.75 (1.37–2.25) 1.00 1.85 (1.03–3.32) 511
1 month 1.86 (1.46–2.38) 1.00 1.79 (1.00–3.20) 488
3 months 2.18 (1.75–2.72) 1.00 1.86 (1.08–3.18) 674
6 months 2.25 (1.83–2.78) 1.00 1.46 (0.86–2.48) 796
1 year 2.25 (1.84–2.74) 1.00 1.50 (0.91–2.47) 971
Male hemorrhagic
Number 121 367 25
Inpatient 1.33 (0.77–2.31) 1.00 3.30 (1.19–9.17) 176
1 month 1.42 (0.83–2.42) 1.00 2.90 (1.08–7.75) 173
3 months 1.39 (0.81–2.39) 1.00 2.08 (0.75–5.78) 200
6 months 1.64 (0.94–2.85) 1.00 1.56 (0.56–4.40) 221
1 year 1.76 (1.01–3.04) 1.00 1.56 (0.56–4.35) 229
Female ischemic
Number 852 2585 216
Inpatient 1.20 (0.97–1.49) 1.00 1.30 (0.87–1.94) 792
1 month 1.29 (1.04–1.60) 1.00 1.49 (1.00–2.21) 733
3 months 1.39 (1.14–1.70) 1.00 1.19 (0.81–1.75) 1007
6 months 1.44 (1.18–1.75) 1.00 1.12 (0.78–1.62) 1159
1 year 1.48 (1.23–1.79) 1.00 1.04 (0.73–1.48) 1328
Female hemorrhagic
Number 95 418 36
Inpatient 1.90 (1.09–3.33) 1.00 2.76 (1.16–6.56) 229
1 month 1.82 (1.06–3.11) 1.00 2.11 (0.92–4.82) 226
3 months 1.80 (1.04–3.13) 1.00 2.08 (0.91–4.77) 256
6 months 2.05 (1.17–3.59) 1.00 2.99 (1.29–6.90) 278
1 year 2.11 (1.19–3.74) 1.00 2.63 (1.14–6.05) 292
The cutoff points were as follows: male: 13.0 and 17.0 g/dL; female: 12.0 and 15.5 g/dL. The variables adjusted for were age, Oxford Community Stroke Project classiﬁcation, prestroke
Rankin Scale score, prior antithrombotic use, coronary heart disease, previous stroke, congestive heart failure, atrial ﬁbrillation, hypertension, hyperlipidemia, diabetes mellitus, peripheral
vascular disease, chronic obstructive pulmonary disease, chronic kidney disease, falls, malignancy, dementia, gastrointestinal bleeding, and peptic ulcer. We also adjusted for International
Normalized Ratio in patients with hemorrhagic stroke. The International Normalized Ratio was included as a dichotomous categorical variable: <1.40 vs ≥1.40. Data for the time points 7
and 14 days were removed for brevity.
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was associated with increased mortality at all time points
assessed, whereas elevated hemoglobin was associated
with increased mortality at 3 time points; inpatient,
6 months, and 1 year.
Table 4 depicts prior antithrombotic use by anemia status
and vascular indication. In women with a positive vascular
indication, those with anemia were less likely to be on prior
antithrombotics compared with those without anemia
(P=0.032). Conversely, in men with a negative vascular
indication, those with anemia were more likely to be on prior
antithrombotics than those without anemia (P<0.001). In
addition, anemia was associated with increased comorbidity
burden in both sexes (Figures 2 and 3).
Systematic Review and Meta-Analysis
Our search identiﬁed 1424 citations. After detailed screening,
20 studies were included in our systematic review; the ﬂow
chart of study selection is shown in Figure 4, and Tables 5 and
6 show the key features of the selected studies. Overall, 10
studies assessed the impact of anemia on stroke1,2,10,16–22 and
10 evaluated the association between stroke and hemoglobin
Table 4. Use of Prior Antithrombotic by Anemia Status and Vascular Indication (Chi-Square Test)
Vascular Indication Yes* Vascular Indication No
Anemia No Anemia P Value Anemia No Anemia P Value
Male 0.971 <0.001
No antithrombotic 237 (34.2) 456 (65.8) 210 (16.3) 1082 (83.7)
Antithrombotic 447 (34.3) 857 (65.7) 123 (23.6) 399 (76.4)
Female 0.032 0.334
No antithrombotic 270 (28.9) 665 (71.1) 229 (17.1) 1114 (82.9)
Antithrombotic 350 (24.9) 1057 (75.1) 98 (19.0) 419 (81.0)
*Indications considered were previous stroke, coronary heart disease, diabetes, hypertension, peripheral vascular disease, and atrial ﬁbrillation.
Figure 4. Flow diagram of study selection.
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Table 5. Characteristics of Studies Examining the Relationship Between Anemia and Hemoglobin Levels and Stroke Outcomes
Author
Years
Sampled Study Design n Exposure Outcomes Main Result
Bhatia et al6 2000–2001 Prospective 116 Admission Hb Mortality at 30 days Hb not associated with outcome
Bussiere et al23 2003–2008 Prospective 2406 Admission Hb
divided into
quintiles—cutoffs:
100, 120, 140,
160 g/L
Mortality at 1 year,
mRS at discharge
Hb predicted mortality at 1 year
(aOR 1.39, 95% CI 1.01–1.91)
in Hb <100 vs 141–160 g/L
Chang et al24 2008–2010 Prospective 106 Admission Hb, nadir
Hb, and transfusion
In-hospital mortality,
length of stay, and
disability at
discharge
Admission anemia did not predict
outcomes
Czlonkowska et al7 1991–1992 Prospective 345 Admission Hb Mortality at 30 days Hb not associated with outcome
Diedler et al25 2004–2006 Prospective 196 Admission, mean
and nadir Hb
mRS at discharge
and 6 months
Admission Hb did not predict
outcomes
Del Fabbro et al16 2001–2003 Retrospective 890 Anemia at admission In-hospital mortality,
survival at 1 year
Higher Hb predicted decreased
mortality at 1 year: HR 0.98
(95% CI 0.97–1.00)
Gray et al26 1985–1986 — 122 Admission Hb Mortality at 4 and
12 weeks
Hb not associated with outcome
Hao et al2 2002–2008 Prospective 1176 Anemia at admission In-patient mortality,
mortality, and
disability (mRS >2)
at 12 months
Anemia associated with inpatient
mortality (aOR 1.66, 95%
CI 1.08–2.56) and mortality
at 12 months (aOR 1.56, 95%
CI 1.05–2.31)
Huang et al17 2001–2003 Prospective 774 Anemia at admission Inpatient mortality,
mRS at discharge,
stroke recurrence
at 3 years
Anemia was associated with
increased mortality at 3 years
(aOR 2.22, 95% CI 1.13–4.39)
Kellert et al8 1998–2009 Prospective 217 Admission, mean
and nadir Hb
Mortality and mRS at
3 months
Hb decrease was associated with
increased mortality at 3 months
(OR 1.34: 1.01–1.76) but
admission Hb was not (OR not
given)
Kumar et al18 1999–2005 Prospective 685 Anemia at admission Mortality at 30 days,
ICH volume
Anemia is not a predictor of
mortality on multivariable
analysis (OR 1.5, 95%
CI 0.9–2.4)
Kuramatsu et al19 2006–2010 Prospective 435 Anemia at admission mRS at 90 days and
1 year
Anemia was associated with
poor long-term outcome
(mRS 4–6 at 1 year; OR 7.5)
Milionis et al20 2003–2011 Retrospective 2439 Anemia at admission Mortality and
disability at
12 months
Anemia associated with mortality
at 12 months (OR 2.70, 95%
CI 2.12–3.43)
Nybo et al21 2003–2004 — 250 Anemia at admission Mortality at
6 months
Anemia associated with greater
risk of death at 6 months
(OR 4.7, 95% CI 1.1–8.2)
Park et al9 2004–2009 Prospective 2681 Admission, nadir,
time-averaged, and
discharge Hb
Mortality and mRS at
3 months
Admission Hb predicted mortality
3 months (aOR: Q1 vs Q3 was
3.74 [95% CI 2.03–6.89] and
Q5 vs Q3 was 1.99 [95%
CI 1.02–3.91])
Continued
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levels.6–9,23–28 In terms of study design, 3 were retrospective
cohort studies,1,16,20 13 were prospective cohort studies,2,6–
10,17–19,22–25 and 2 were secondary analyses of randomized
control trials.27,28 There were also 2 studies that did not state
the design.21,26 There was a high degree of diversity in
geographic location, with cohorts fromGermany,8,19,25 Switzer-
land,16,20 the United States,18,24 the People’s Republic of
China,2,22 Canada,23,28 India,6 Israel,10 the Republic of Korea,9
Denmark,21 Taiwan,17 the United Kingdom,26 and Poland.7 In
addition, 2 studies were conducted across multiple coun-
tries.1,27 Regarding stroke type, 9 studies assessed patients
with ischemic stroke,1,2,8,9,17,20,21,27,28 6 assessed patients
with hemorrhagic stroke,9,18,22–25 and 5 evaluated both types
of stroke.6,7,10,16,26 The number of participants in the studies
ranged from 106 to 3020.When combinedwith the participants
from the current study, the total pooled study population
included 29 943 participants of whom 24 816 were meta-
analyzed. ORs included in the meta-analysis were from the
mortality time point of 1 year or the closest time point available
to 1 year.
Validity Assessment
Different methods were used for ascertainment of stroke
diagnosis. Imaging (computed tomography, magnetic reso-
nance imaging, or both) was used in 17 studies,1,2,6–8,10,17–
25,27,28 1 study relied on clinical evaluation alone,26 and 2 did
not state the method used.9,16 The methods used to ascertain
mortality also varied. Attending doctors conﬁrmed in-hospital
mortality in 2 studies,24,25 whereas death registry data were
used in 4 studies.10,20,21,23 Telephone interviews were used
by 7 studies, typically in conjunction with other methods such
as outpatient visit, home visit, mailed questionnaire, analysis
of death registries, or review of medical records.6,8,9,16,18,19,22
One study used outpatient visits only,17 and the method used
to establish mortality status was unclear in 6 studies.1,2,7,26–
28 Despite the variety of approaches taken to ascertain
mortality, all seemed reliable.
Eleven studies used the World Health Organization deﬁni-
tion of anemia as hemoglobin cutoffs,2,8,10,16–22,24 7 used
prespeciﬁed values,1,9,23,25–28 and 2 did not specify the values
used.6,7 By using prespeciﬁed thresholds in constructing
categorical comparisons for anemia, it is possible that cut
points have been drawn up that favor statistically signiﬁcant
ﬁndings. Eighteen studies adjusted for potential con-
founders1,2,7–10,16–27; however, there was great variation in
terms of the variables adjusted for. These included age and
National Institutes of Health Stroke Scale1 as well as age, sex,
insurance status, smoking, time to treatment, type of
intervention, prestroke medication, body mass index, blood
pressure, heart rate, Trial of Org 10172 Acute Stroke
Treatment criteria classiﬁcation, metabolic parameters, and
comorbidities.20 Consequently, many studies were liable to
residual confounding (Table 6).
Table 5. Continued
Author
Years
Sampled Study Design n Exposure Outcomes Main Result
Sharma et al27 2003–2011 Post hoc
analysis of RCT
3020 Admission Hb and
Hb <13 g/dL
All-cause mortality Hb <13 g/dL was a significant
predictor of mortality (HR 1.60,
95% CI 1.22–2.10)
Sico et al1 1998–2003 Retrospective 1306 Anemia at admission Inpatient mortality or
discharge to
hospice (combined
end point)
Anemia was associated with
outcome in patients with less
severe stroke on subgroup
analysis (aOR 4.17, 95%
CI 1.47–11.90)
Tanne et al10 2001–2002 Prospective 859 Anemia at admission Mortality at 1 month
and 1 year,
functional outcome
using Barthel Index
aOR for mortality at 1 month was
1.90 (95% CI 1.05–3.43) and at
1 year was 1.72 (95% CI 1.00–
2.93)
Wade et al28 1977–1982 Post hoc
analysis of RCT
1377 Hb >15 vs ≥15 g/dL
on study entry
Fatal and nonfatal
strokes
No significant difference in Hb
levels among those who died
compared with survivors
Zeng et al22 2007–2008 Prospective 2513 Anemia on
admission
Mortality and
dependency (mRS
>2) at 1, 3, 6, and
12 months
aOR for mortality in anemic
versus nonanemic patients:
6 months 1.34 (95% CI 1.01–
1.78), 1 year 1.33 (95%
CI 1.00–1.75)
aOR indicates adjusted odds ratio; Hb, hemoglobin; HR, hazard ratio; ICH, intracerebral hemorrhage; mRS, modiﬁed Rankin Scale score; OR, odds ratio; Q, quintile; RCT, randomized
controlled trial.
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Meta-analyses of pooled results showed that anemia is
associated with an increased risk of mortality in ischemic
stroke (pooled OR 1.97, 95% CI 1.57–2.47) (Figure 5).We also
found a signiﬁcant association for the evaluation of anemia
and mortality in hemorrhagic stroke, albeit at a lower
magnitude of association (OR 1.46, 95% 1.23–1.74) (Fig-
ure 6).The number of studies providing ORs for the relation-
ship between elevated hemoglobin and stroke mortality was
insufﬁcient for a meta-analysis to be conducted. Although
available data suggest that elevated hemoglobin predicts
short-term mortality in ischemic stroke, ﬁndings are less
consistent for hemorrhagic stroke (Table 7). The funnel plot
depicting ORs for mortality in anemic ischemic stroke patients
shows asymmetry (Figure 7), with an underrepresentation of
studies on the left side that we would typically expect to
consist of those reporting no signiﬁcant harm in the
relationship between anemia and stroke mortality. We
encountered 5 such studies that reported no signiﬁcant
association in our systematic review that we could not
incorporate into the meta-analysis because ORs were not
given, causing asymmetry in the funnel plot.
Discussion
Our study examined the association between anemia and
hemoglobin levels and mortality in acute stroke in a large
unselected stroke patient population and sought to quantify
this association using systematic review and meta-analysis. At
24.5%, prevalence of anemia was high in the cohort analyzed
in the current study. Low hemoglobin levels were associated
with older age, increased stroke severity, higher prestroke
disability, and the increased comorbidity burden. This sug-
gested that outcomes were mediated by the impact of
confounders; however, we found anemia to be independently
associated with mortality subsequent to making the appro-
priate adjustments. A systematic review and meta-analysis of
the literature conﬁrmed our ﬁndings. In addition, we found
elevated hemoglobin to be associated with poorer outcomes
in acute stroke, suggesting a U-shaped relationship between
hemoglobin levels and stroke mortality.
The literature has described several pathological mecha-
nisms that can plausibly explain the independent association
between anemia and increased mortality risk in stroke. First, by
lowering the oxygen-carrying capacity of blood, anemia may
intensify ischemia and thus hypoxia within the penumbral
lesions in patients with ischemic stroke.29,30 Second, anemia
can compromise cerebrovascular autoregulation, leading to
ﬂuctuations in cerebral perfusion; this alters the delivery of
oxygen to the brain,31,32 thereby exacerbating damage caused
by ischemia or hemorrhage. Third, augmentation of cerebral
blood ﬂow can create turbulence, which can trigger the
migration of an existing thrombus and lead to aT
ab
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thromboembolism.33 Fourth, anemia may lead to hyperdy-
namic circulation, which has been shown to modulate the
expression of adhesion molecules on vascular endothelial cells
by upregulating their production. This may trigger an inﬂam-
matory response that leads to thrombus formation in a process
similar to atherosclerosis.34,35 Fifth, anemia may worsen
outcomes in stroke because of its relationship with inﬂamma-
tory mediators; it can upregulate the production of inducible
nitric oxide synthase and CXC chemokine receptor 4,36 both of
which have been associated with brain damage during
ischemia.37,38
In addition to the pathophysiological mechanisms
described, there is also a plausible clinical explanation for
the excess mortality risk in stroke patients with anemia. It
may be the case that anemic patients were less likely to be
prescribed antithrombotics because of the increased risk of
bleeding. This was suggested by a ﬁnding shown in Table 4 in
which fewer anemic women who had a positive vascular
indication were on prior antithrombotics compared with those
without anemia. This ﬁnding potentially supports the well-
documented differential management of cardiovascular risk
factors between sexes. The reverse trends were observed for
Study or Subgroup
1.1.1 Categorical Anemia
Current Study Female Ischemic
Current Study Male Ischaemic
Hao 2013
Huang 2009
Milionis 2014
Nybo 2007
Sharma 2014
Tanne 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 25.66, df = 7 (P = 0.0006); I² = 73%
Test for overall effect: Z = 5.45 (P < 0.00001)
1.1.2 Lowest vs. referent
Park 2013
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.23 (P < 0.0001)
Total (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 31.34, df = 8 (P = 0.0001); I² = 74%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi² = 4.47, df = 1 (P = 0.03), I² = 77.6%
Weight
15.4%
15.2%
11.3%
6.8%
13.4%
8.5%
13.8%
7.9%
92.3%
7.7%
7.7%
100.0%
IV, Random, 95% CI
1.48 [1.23, 1.79]
2.25 [1.84, 2.74]
1.56 [1.05, 2.32]
2.22 [1.12, 4.39]
1.35 [1.01, 1.80]
4.70 [2.69, 8.20]
1.60 [1.22, 2.10]
1.90 [1.05, 3.44]
1.85 [1.49, 2.32]
3.74 [2.03, 6.89]
3.74 [2.03, 6.89]
1.97 [1.57, 2.47]
Odds Ratio Odds Ratio
IV, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Anaemia not harmful Anaemia harmful
Figure 5. Meta-analysis of studies analyzing the impact of anemia at admission on mortality in ischemic
stroke. IV indicates inverse variance.
Study or Subgroup
Bussiere 2013
Current Study Female Hemorrhagic
Current Study Male Hemorrhagic
Kumar 2009
Zeng 2014
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.58, df = 4 (P = 0.63); I² = 0%
Test for overall effect: Z = 4.30 (P < 0.0001)
Weight
29.9%
9.2%
10.0%
11.6%
39.2%
100.0%
IV, Random, 95% CI
1.39 [1.01, 1.91]
2.11 [1.19, 3.74]
1.76 [1.01, 3.04]
1.50 [0.90, 2.50]
1.33 [1.00, 1.75]
1.46 [1.23, 1.74]
Odds Ratio Odds Ratio
IV, Random, 95% CI
0.5 0.7 1 1.5 2
Anemia not harmful Anemia harmful
Figure 6. Meta-analysis of studies analyzing the impact of anemia at admission on mortality in
hemorrhagic stroke. IV indicates inverse variance.
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those without vascular indications, supporting previous
observations that inappropriate prescribing may be more
prevalent for women.
The association between anemia and mortality suggests
that interventions may improve outcomes. Although previous
studies have shown that packed red blood cell transfusions
reduce mortality at 30-days in anemic patients with myocar-
dial infarction,39 a recent systematic review and meta-analysis
found that blood transfusion after percutaneous coronary
intervention is associated with adverse outcomes,40 casting
doubt on the potential beneﬁts of packed red blood cell
transfusions in anemic stroke patients. Observational studies
reporting the association between mortality and transfusion in
anemic patients with hemorrhagic stroke have had varied
results, with one ﬁnding a reduction in mortality41 and
another ﬁnding no change.18 To the knowledge of the authors,
no studies assessing the impact of packed red blood cell
transfusion on anemic ischemic stroke patients have been
conducted. Because of the paucity of evidence, guidelines
have been unable to specify hemoglobin targets or optimal
management options.11 A randomized controlled trial is
required to gauge the impact of transfusions and to establish
optimum hemoglobin ranges in patients with acute stroke.
Our study has a number of strengths. The stroke cases were
prospectively identiﬁed, and the cohort had almost complete
follow-up using validated methods. Because a large sample
population was used, it was possible to conduct a rigorous
analysis by sex and stroke type, enabling us to provide new
insights. We were also able to control for a diverse array of
confounders, thereby mitigating the effects of residual con-
founding. The meta-analysis included patients from a wide
array of countries, increasing the generalizability of our
ﬁndings. The inclusion of a large number of participants in
themeta-analysis provided sufﬁcient statistical power to obtain
results for both stroke subtypes. Finally, all studies included in
the meta-analysis were of high methodological quality.
Table 7. Odds Ratios From Studies Evaluating Association Between Elevated Hemoglobin and Stroke Mortality
Study
Deﬁnition of Elevated
Hemoglobin
Mortality
Time Point
Number
of Patients
Odds Ratio
(95% CI)
Ischemic stroke
Park et al9 Prespecified quintile 3 months 2681 1.99 (1.02–3.91)
Current study, men >17 g/dL In-patient 3298 1.85 (1.03–3.32)
1 month 1.79 (1.00–3.20)
3 months 1.86 (1.08–3.18)
6 months 1.46 (0.86–2.48)
1 year 1.50 (0.91–2.47)
Current study, women >15.5 g/dL In-patient 3653 1.30 (0.87–1.94)
1 month 1.49 (1.01–2.21)
3 months 1.19 (0.81–1.75)
6 months 1.12 (0.78–1.62)
1 year 1.04 (0.73–1.48)
Hemorrhagic stroke
Bussiere et al23 >16 g/dL 1 year 2406 1.00 (0.74–1.33)
Current study, men >17 g/dL In-patient 3.20 (1.19–9.17)
1 month 2.90 (1.08–7.75)
3 months 2.08 (0.75–5.78)
6 months 1.56 (0.56–4.40)
1 year 513 1.56 (0.56–4.35)
Current study, women >15.5 g/dL In-patient 549 2.76 (1.16–6.56)
1 month 2.11 (0.92–4.82)
3 months 2.08 (0.91–4.77)
6 months 2.99 (1.29–6.90)
1 year 2.63 (1.14–6.05)
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This study has some limitations. The small sample number
of patients with hemorrhagic stroke may have contributed to
the nonsigniﬁcant P values. Some of the models used did not
ﬁt the data well. Hosmer–Lemeshow tests were signiﬁcant for
ischemic stroke in men at 3 and 6 months and 1 year
(Table 2). Although this result does not alter the associations
found, it indicates that for this subgroup, there may be other
factors or interactions that might help better predict mortality
outcome at these time points. It is possible that we were not
able to control for unknown factors. In this registry-based
study, we were not able to fully adjust for treatment effect (eg,
blood transfusion, use of iron supplements and erythropoietin-
stimulating agents). Nonetheless, transfusion for mild to
moderate anemia in stroke is not a routine practice, and the
likelihood of such confounding is minimal. We were unable to
consider the duration of anemia or to assess the impact of
abnormal hemoglobin levels subsequent to a stroke; there-
fore, the independent association between anemia and excess
mortality in stroke cannot be described as a causal relation-
ship. The studies in the meta-analysis had high heterogeneity
for ischemic stroke (I2>50%). Finally, the possibility of
underrepresentation of studies that reported no signiﬁcant
harm in the relationship between anemia and stroke mortality
raises the issue of selective reporting. Consequently, our
meta-analysis may have overinﬂated estimates of the asso-
ciation between anemia and excess mortality risk.
In conclusion, we showed that a signiﬁcant proportion of
stroke patients have anemia at the time of stroke onset and
that this is associated with increased mortality up to 1 year.
The optimal treatment option in this patient group is unclear.
Studies are required to examine the clinical and cost-
effectiveness of interventions in this patient population in
an acute stroke setting.
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